Bonus Biogroup, a Phase 2 Israeli biotech developing cell therapies for bone regeneration and respiratory indications, filed on Friday with the SEC to raise up to $20 million in an initial public offering. The company is currently listed on the Tel Aviv Stock Exchange under the symbol "BONS".
The company's two lead product candidates are BonoFill, a personalized, autologous tissue-engineered live-human bone graft, and MesenCure, an enhanced allogeneic cell therapy for inflammation and tissue damage. BonoFill completed a Phase 2 trial in maxillofacial bone defects in the upper and lower jaw bones for sinus augmentation and void filling, and is currently in a Phase 2 trial in defects in long and short limb bones incapable of self-healing or untreatable by standard techniques, with interim results expected in early 2026. MesenCure completed a Phase 2 trial for pulmonary manifestations of COVID in severely ill patients in 2022, and in February received clearance for a Phase 3 trial. The company plans to initiate a trial of MesenCure in all-cause respiratory distress in late 2025.
The Haifa, Israel-based company was founded in 1981 and plans to list on the Nasdaq under the symbol BONS. Bonus Biogroup filed confidentially on February 27, 2025. Titan Partners is the sole bookrunner on the deal. No pricing terms were disclosed.
